William Blair

William Blair Sees Limited Downside Potential for Finisar Corporation (FNSR) in Light of Setback in 3-D Production

Strong datacom market drivers could spur revenue growth in second half of fiscal 2018, says analyst.

Gilead Sciences, Inc. (GILD) Has Solid Catalysts for Continued Growth; William Blair Sets Fair Value at $87

Kite acquisition signals Gilead’s leadership and continued consolidation moving forward, says Katherine Xu

Nutanix Inc’s (NTNX) Hyperconverged Infrastructure Market Standing Looks Strong Ahead of FQ4 Print

William Blair Values Nutanix’s Exciting Momentum in U.S.

What’s Next for QUALCOMM, Inc.’s (QCOM) Licensing Business? William Blair Weighs In

Skepticism Circles Qualcomm’s Licensing Business Following President’s Departure

Abercrombie & Fitch Co. (ANF) 2Q17 Beat Shows Encouraging Momentum: William Blair

Analyst Sees Long-Term Benefits for A&F and Hollister Thanks to New Loyalty Program Launches

Chipotle Mexican Grill, Inc. (CMG) Regaining Consumer Confidence, Says William Blair

18 to 29 Year-Olds Least Worried About Food Safety at Chipotle

Ulta Beauty Inc (ULTA) Well-Positioned Heading into Q2 Print: William Blair

Ulta Beauty Inc (NASDAQ:ULTA) will release second quarter results on Thursday, August 24th and analyst Daniel Hofkin of William Blair is out with a …

Endo International plc – Ordinary Shares (ENDP) Near-Term Challenges Offset 2Q Earnings Beat

Despite Endo International plc – Ordinary Shares (NASDAQ:ENDP) delivering a second-quarter earnings beat on Tuesday, with the management team forced to pull back …

William Blair Boosts Price Target for Dynavax Technologies Corporation (DVAX) as VRBPAC Panel Gives Thumbs Up to Heplisav

William Blair analyst Y Katherine Xu is out with a bullish note on shares of Dynavax Technologies Corporation (NASDAQ:DVAX), after the FDA’s Vaccines and Related Biological …

William Blair Bullish on Biotech: Sarepta Therapeutics Inc (SRPT), Dynavax Technologies Corporation (DVAX), and Exelixis, Inc. (EXEL)

Sarepta’s $12+ Million 2Q Beat Sarepta Therapeutics Inc (NASDAQ:SRPT) Duchenne muscular dystrophy (DMD) drug Exondys 51 (eteplirsen) has outclassed expectation, leading the biotech …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts